A Custom-Built Protein to Block TGF-beta Signaling in Disease

A laboratory-engineered protein designed to soak up excess TGF-beta molecules, which could help treat conditions like cancer and fibrosis where these signals are overactive.

What it covers

This patent describes a synthetic protein called RER, which is a fusion of parts from two different human receptors: TGF-beta type II and type III. By stitching these together into a heterotrimeric structure, the protein acts like a molecular sponge that binds to all three isoforms of TGF-beta with high affinity. Because it specifically targets TGF-beta, it can neutralize these signals without interfering with other related growth factors like BMPs or activins. In practice, this could be injected into a patient to clear out harmful, excess TGF-beta signaling that drives tumor growth or tissue scarring.

What it doesn't cover

• —Does not cover naturally occurring TGF-beta receptors found in the human body.
• —Does not cover fusion proteins that bind to other TGF-beta superfamily members like BMPs or activins.
• —Does not cover general protein engineering techniques that do not result in the specific RER heterotrimeric structure.
• —Does not cover therapeutic methods that do not rely on the specific amino acid sequences defined in the claims.

The clever bit

The innovation lies in combining the ectodomains of two distinct receptors into a single, stable heterotrimeric fusion that achieves high-affinity binding to all three TGF-beta isoforms simultaneously, a feat that single-receptor approaches struggle to match.

Why it matters

TGF-beta is a major signaling protein involved in both healthy tissue repair and dangerous disease progression. By creating a highly specific 'sink' for this protein, researchers aim to stop diseases like cancer and fibrosis at the source. This is a significant step in developing targeted biological therapies that avoid the broad side effects of systemic drugs.

Real-world examples

• 1.Experimental cancer therapies targeting the tumor microenvironment
• 2.Anti-fibrotic research treatments for organ scarring